'These medications need to be widely available and promoted immediately for physicians to prescribe,' the American Journal of Epidemiology says.
prestigious medical journal is criticizing news media coverage of hydroxychlorioquine in the battle against coronavirus, saying there is evidence the anti-malarial drug combined with the antibiotic azithromycin helps in the early stages of outpatient treatment.
"These medications need to be widely available and promoted immediately for physicians to prescribe," the American Journal of Epidemiology reported in an article published this week that pushed back against claims the regimen has been dangerous or ineffective in all cases.
"Hydroxychloroquine plus azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September," the journal noted, urging medical professionals and the public to recognize there are different stages of the disease that may require different treatments.
The article said the two candidate medications which have been widely reported - remdesivir and hydroxychloroquine plus azithromycin -- need to be looked at differently.
"Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients," it said.
Meanwhile, the regimen with hydroxychloroquine has been the subject of five studies, including two controlled clinical trials, that "have demonstrated significant major...
Read More HERE
No comments:
Post a Comment